Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

被引:87
|
作者
Mai, A
Sbardella, G
Artico, M
Ragno, R
Massa, S
Novellino, E
Greco, G
Lavecchia, A
Musiu, C
La Colla, M
Murgioni, C
La Colla, P
Loddo, R
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, I-00185 Rome, Italy
[3] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[4] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[5] Novirio Pharmaceut Inc, Boston, MA USA
[6] Univ Cagliari, Sez Microbiol, Dipartimento Biol Sperimentale, I-09042 Cagliari, Italy
关键词
D O I
10.1021/jm010853h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
5-Alkyl-2-(alkylthio)-6-(2,6-difluorobenzyl)-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs, 2) have been recently described as a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) active at nanomolar concentrations (Mai, A. et al. J. Med. Chem. 1999, 42, 619-627). In pursuing our lead optimization efforts, we designed novel conformationally restricted S-DABOs, 3, featuring a methyl at the benzylic carbon (Y = Me) and at the pyrimidine 5-position (R = Me). Conformational analyses and docking simulations suggested that the presence of both methyls would significantly reduce conformational flexibility without compromising, in the R enantiomers, the capability of fitting into the RT non-nucleoside binding pocket. To develop structure-activity relationships, we prepared several congeners of type 3 belonging to the thymine (R = Me) and uracil (R = H) series, featuring various 2-alkylthio side chains (X = Me, i-Pr, n-Bu, i-Bu, s-Bu, c-pentyl, and c-hexyl) and aryl moieties different from the 2,6-difluorophenyl (Ar = phenyl, 2,6-dichlorophenyl, 1-naphthyl). Moreover, alpha -ethyl derivatives (Y = Et) were included in the synthetic project in addition to alpha -methyl derivatives (Y = Me). All of the new compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells, and some of them were assayed against highly purified recombinant wild-type HIV-1 RT using homopolymeric template primers. The results were expressed as CC50 (cytotoxicity), EC50 (anti-HIV-1 activity), SI (selectivity, given by the CC50/EC50 ratio), and IC50 (RT inhibitory activity) values. In the 2,6-difluorobenzylthymine (R = Me) series, methylation of the benzylic carbon improved anti-HIV-1 and RT inhibitory activities together with selectivity. Compound 3w (Ar = 2,6-F-2-Ph, R = Y = Me, X = c-pentyl) turned out the most potent and selective among the S-DABOs reported to date (CC50 > 200 muM, EC50 = 6 nM, IC50 = 5 nM, and SI > 33 333). Assays performed on the pure enantiomer (+)-3w, much more active than (-)-3w, yielded the following results: CC50 > 200 muM, EC50 = 2 nM, IC50 = 8 nM, and SI > 100 000, under conditions wherein MKC-442 was less active and selective (CC50 > 200 muM, EC50 = 30 nM, IC50 = 40 nM, SI > 6666). The 2,6-difluorophenylethylthymines (R = Me) were generally endowed with higher potency compared with the uracil counterparts (R = H). In the 2,6-difluorophenyl series the best and the least performant 2-alkylthio side chains were the 2-c-pentylthio and the 2-methylthio, respectively. When the methyl at the benzylic carbon was replaced by an ethyl, activity was retained or decreased slightly, thus suggesting that the dimensions of the cavity within the RT hosting this substituent would not be compatible with groups larger than ethyl. Aryl moieties different from the 2,6-difluorophenyl (phenyl, 1-naphthyl, 2,6-dichlorophenyl) were generally detrimental to activity, consistent with a favorable electronic effect exerted by the 2,6-fluorines on a putative charge-transfer interaction between the aromatic moieties of the inhibitor and Tyr188.
引用
收藏
页码:2544 / 2554
页数:11
相关论文
共 50 条
  • [31] Synthesis, molecular docking and biological evaluation of 2-(thiophen-2-yl)-1H-indoles as potent HIV-1 non-nucleoside reverse transcriptase inhibitors
    El-Hussieny, Marwa
    El-Sayed, Naglaa F.
    Ewies, Ewies F.
    Ibrahim, Nabila M.
    Mahran, Mohamed R. H.
    Fouad, Marwa A.
    BIOORGANIC CHEMISTRY, 2020, 95
  • [32] Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors
    Murugesan, Vanangamudi
    Tiwari, Vinay S.
    Saxena, Reshu
    Tripathi, Rajkamal
    Paranjape, Ramesh
    Kulkarni, Smita
    Makwana, Nandini
    Suryawanshi, Rahul
    Katti, Seturam B.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (22) : 6919 - 6926
  • [33] Non-nucleoside HIV-1 reverse-transcriptase inhibitors -: Part 10 -: Synthesis and anti-HIV activity of 5-Alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'Dihydro-Alkoxy-Benzyl-Oxopyrimidine' (DABO) analogues
    Wang, Yueping
    Chen, Fen-Er
    Balzarini, Jan
    De Clercq, Erik
    Pannecouque, Christophe
    CHEMISTRY & BIODIVERSITY, 2008, 5 (01) : 168 - 176
  • [34] Synthesis and Antiviral Properties of New Derivatives of 2-(Alkylsulfanyl)-6-[1-(2,6-difluorophenyl)cyclopropyl]-5-methylpyrimidin-4(3H)-one
    Novakov, I. A.
    Yablokov, A. S.
    Orlinson, B. S.
    Navrotskii, M. B.
    Kirillov, I. A.
    Vernigora, A. A.
    Babushkin, A. S.
    Kachala, V. V.
    Schols, D.
    RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, 2016, 52 (08) : 1188 - 1193
  • [35] Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation
    De Martino, G
    La Regina, G
    Di Pasquali, A
    Ragno, R
    Bergamini, A
    Ciaprini, C
    Sinistro, A
    Maga, G
    Crespan, E
    Artico, M
    Silvestri, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (13) : 4378 - 4388
  • [36] Synthesis and antiviral properties of new derivatives of 2-(alkylsulfanyl)-6-[1-(2,6-difluorophenyl)cyclopropyl]-5-methylpyrimidin-4(3H)-one
    I. A. Novakov
    A. S. Yablokov
    B. S. Orlinson
    M. B. Navrotskii
    I. A. Kirillov
    A. A. Vernigora
    A. S. Babushkin
    V. V. Kachala
    D. Schols
    Russian Journal of Organic Chemistry, 2016, 52 : 1188 - 1193
  • [37] Anti-HIV agents .4. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazoles
    Chimirri, A
    Grasso, S
    Molica, C
    Monforte, AM
    Monforte, P
    Zappala, M
    Scopelliti, R
    FARMACO, 1996, 51 (04): : 279 - 282
  • [38] Synthesis and Biological Evaluation of 6-Substituted 5-Alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as Potent HIV-1 NNRTIs
    Yu, Mingyan
    Li, Zhenyu
    Liu, Shuai
    Fan, Erkang
    Pannecouque, Christophe
    De Clercq, Erik
    Liu, Xinyong
    CHEMMEDCHEM, 2011, 6 (05) : 826 - 833
  • [39] Synthesis, evaluation and molecular modelling studies of some novel 3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(substituted-phenyl)propanamides as HIV-1 non-nucleoside reverse transcriptase inhibitors
    Murugesan, S.
    Ganguly, Swastika
    Maga, Giovanni
    JOURNAL OF CHEMICAL SCIENCES, 2010, 122 (02) : 169 - 176
  • [40] 5-alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: Novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives
    Mai, A
    Artico, M
    Sbardella, G
    Massa, S
    Novellino, E
    Greco, G
    Loi, AG
    Tramontano, E
    Marongiu, ME
    La Colla, P
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (04) : 619 - 627